Royce & Associates LP Alector, Inc. Transaction History

Royce & Associates LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 12, 2020	SELL	$10.54 - $24.96 $10,824 - $25,633	-1,027 Closed	0 $0
Q2 2020 Aug 07, 2020	SELL	$21.87 - $33.11 $3,302 - $4,999	-151 Reduced 12.82%	1,027 $25,000
Q1 2020 May 12, 2020	SELL	$16.25 - $35.28 $7,670 - $16,652	-472 Reduced 28.61%	1,178 $28,000
Q4 2019 Feb 06, 2020	SELL	$14.17 - $20.3 $2,975 - $4,263	-210 Reduced 11.29%	1,650 $28,000
Q3 2019 Nov 13, 2019	BUY	$14.42 - $22.2 $10,915 - $16,805	757 Added 68.63%	1,860 $27,000
Q2 2019 Aug 12, 2019	BUY	$16.26 - $26.42 $17,934 - $29,141	1,103 New	1,103 $21,000

167

57.8M

146K

90.8K

Ticker ALEC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,563,904
Market Cap $149M
Description
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

Stay updated on Royce & Associates LP with notifications on news.